Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
In February 2000, a pneumococcal conjugate vaccine was licensed for use in the USA. This vaccine has been shown to be effective in reducing pneumococcal disease, and has been recommended for universal use in infants. However, pneumococcal conjugate vaccine is by far the most expensive child vaccine series routinely administered in the USA, alone accounting for over 40% of the total purchase price of vaccines for the recommended childhood schedule. This article reviews the existing efficacy and economic studies of pneumococcal conjugate vaccine and discusses the process by which routine use of pneumococcal conjugate vaccine was introduced and the role economic analysis played in that process. Some of the scientific and funding issues relating to its use in both the industrialized and developing world are also discussed.
Ray
G Thomas
GT
Division of Research, Kaiser Permanente, Oakland, CA 94612-2304, USA. tom.ray@kp.org
D000818:Animals; D002648:Child; D003906:Developing Countries; D017277:Drug Approval; D006801:Humans; D011008:Pneumococcal Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics / Q000276:immunology*; D014481:United States; D014486:United States Food and Drug Administration; D018074:Vaccines, Conjugate / Q000191:economics / Q000276:immunology*
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate